Drugmakers Grünenthal and Mesoblast entered into a partnership to develop a biologics-based treatment for chronic lower back pain.
The companies are developing and commercializing MPC-06-ID, a phase 3 allogeneic cell therapy candidate. The companies hope the therapy can treat chronic lower back pain caused by degenerative disc disease. If successful, Grünenthal will have commercialization rights to the drug in Europe and Latin America.